Loading ...

Blob

Smart Reasoning:

C&E

See more*

Qaagi - Book of Why

Causes

Effects

the required period maintenance feescausingthe patent to expire

Someoneinventedthe patent expire

knowhas ledto some minor patent expiration

Streptococcus two gram dosage of zithromax with levoflaxacin via the liver caution(passive) caused byzithromax patent expiration

by the need to obtain a marketing authorisation before the product can be marketed(passive) caused bypatent term

by the need to obtain a marketing authorisation(passive) caused bypatent term

with smoke(passive) is often paintedPatent term

by applicant 's delay(passive) caused bypatent term

Failure to pay the current maintenance fee on timemay resultin expiration of the patent

Failure to pay the current maintenance fee on timemay resultin expiration of the patent

by injury(passive) caused bylansoprazole patent expiration

the effectcausea looming patent expiration

A patent may not have its term extended after the termination of the patent term , therefore failure to file an applicationwill resultin the expiration of the patent

Failure to pay the feemay resultin expiration of the patent

DrugscausedPatent Ductus

arteriosus(passive) can be causedPatent ductus

the riskresultingfrom patent expiration

the loss in profitresultedfrom the expiration of the patent

these deadlinesmay resultin expiration of the patent

the dedicationresultingfrom the expiration of the patents

the time necessary to process and review an application for patent term extensionmight resultin a patent expiring

Profits lossesresultingfrom patent expiry

the term of a patent for up to one year if the time necessary to process and review an application for patent term extensionmight resultin a patent expiring

Revenue lossesresultingfrom patent expiry

maintenance fees ... the patent officeresultsin the patent expiring

Failure to pay the maintenance fee on timewill resultin the patent expiring

of rights granted to an inventor by national government for some time period in exchange of public disclosure of that invention(passive) is setPatent

the first Irish companyto designpatent

to protect and encourage innovation(passive) was inventedPatent

patents are being invented(passive) was inventedpatent

to protect ideas , systems , or methods of operation(passive) is designedPatent

an interest in any patent application orresultingpatent

The identity of inventors in a patent application has a bearing on ownership of the invention andresultingpatent

to expire(passive) is currently setpatent

by its inventor(passive) was contributed bypatent

informationto resultpatent

Inc. Design which is not entitledto designpatent

Our firmhas inventedpatent

this issue ... enoughto designpatent

the problemcausingpatent

to a rapid increase in the number of newly treated patientsledto a rapid increase in the number of newly treated patients

paincausingpain

sales to decline , or new competition , which we 'll talk about in a second , or new drug launchescausingsales to decline , or new competition , which we 'll talk about in a second , or new drug launches

to a rapid increase in the number of newly treated patients , with an appreciable number prescribed generic atorvastatin ( 50.9 % in June 2010ledto a rapid increase in the number of newly treated patients , with an appreciable number prescribed generic atorvastatin ( 50.9 % in June 2010

in particularcan resultin particular

in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America

in the sluggish growth rate of the adalimumab market in Latin Americahas resultedin the sluggish growth rate of the adalimumab market in Latin America

within - patent competition(passive) caused bywithin - patent competition

enough competition in the markethas ... causedenough competition in the market

to price competitionthereby leadingto price competition

the loss(passive) caused bythe loss

in limited generic competitionresultsin limited generic competition

to massive revenue lossescan leadto massive revenue losses

to declining salesmay leadto declining sales

the overall sales risk(passive) caused bythe overall sales risk

to the increasing launch of generic drugsleadsto the increasing launch of generic drugs

to massive falls in sales of the originalleadsto massive falls in sales of the original

to onesetto one

the loss(passive) caused bythe loss

earnings and revenues to declineto causeearnings and revenues to decline

in stiff competition from other drugswill ... resultin stiff competition from other drugs

sales to drop by more thancan causesales to drop by more than

to manufacturing of genericsleadingto manufacturing of generics

to massive falls in sales of the original as generics steal market share etcleadsto massive falls in sales of the original as generics steal market share etc

in a smallcausein a small

to the manufacturing of generic drugs , which can be leveraged by the generic manufacturesleadsto the manufacturing of generic drugs , which can be leveraged by the generic manufactures

nothinginventednothing

for August 20 , 2020setfor August 20 , 2020

to the introduction of new biosimilarswill leadto the introduction of new biosimilars

to massive fallsleadsto massive falls

to an abrupt drop in sales Provisional patent application Submarine patent Supplementary protection certificate ( SPCleadsto an abrupt drop in sales Provisional patent application Submarine patent Supplementary protection certificate ( SPC

oftenresultsoften

to take place on october 15 , 2017is setto take place on october 15 , 2017

to the introduction of new entrantsleadingto the introduction of new entrants

to diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approvedmay leadto diminution of its market share ... but can not reasonably be considered either imminent or necessarily drastic as Keryx was the only company to apply for a new drug application and it was not yet approved

to a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosionwill leadto a loss in revenues of over USD 1bn ... EUR 734 m ... in 2008 ... due to generic sales erosion

to the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such productsleadsto the availability of highly similar , safe and effective biotech products that are more reasonably priced and more affordable for patients requiring treatment with such products

to a 60 - 70 per cent crash in drug pricesusually leadsto a 60 - 70 per cent crash in drug prices

to a dramatic increase in its use , including applications to fields during growing seasonledto a dramatic increase in its use , including applications to fields during growing season

to a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest sellerledto a 35 % decrease in 2006 sales for depression drug Zoloft , Pfizer 's third - highest seller

Blob

Smart Reasoning:

C&E

See more*